ABBOTT LABORATORIES
424B2, 1995-05-11
PHARMACEUTICAL PREPARATIONS
Previous: VOYAGEUR TAX EXEMPT TRUST SERIES 3, S-6EL24/A, 1995-05-10
Next: ADVANCE ROSS CORP, 10-Q, 1995-05-11



<PAGE>
           PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED OCTOBER 1, 1993

                                  $150,000,000
                              ABBOTT LABORATORIES
                          6.80% NOTES DUE MAY 15, 2005
                                 -------------

    Interest  on the Notes is payable semi-annually on May 15 and November 15 of
each year,  beginning  November  15,  1995. The  Notes  are  not  redeemable  or
repayable prior to maturity and do not provide for any sinking fund.

    The Notes will be represented by one or more Global Securities registered in
the  name of  the nominee  of The  Depository Trust  Company, which  will act as
Depository. Interests  in  Global Securities  will  be evidenced  only  by,  and
transfers  thereof will be effected only  through, records maintained by DTC and
its participants. Except as  described in the  Prospectus, owners of  beneficial
interests  in a Global Security  will not be considered  the Holders thereof and
will not be entitled to receive  physical delivery of Notes in definitive  form.
See  "Description  of  Notes." The  Notes  will  trade in  DTC's  Same-Day Funds
Settlement System  and secondary  market  trading activity  for the  Notes  will
therefore  settle in immediately available funds.  All payments of principal and
interest will  be made  by the  Company in  immediately available  funds or  the
equivalent. See "Description of Notes."

                               ------------------

THESE  SECURITIES HAVE  NOT BEEN APPROVED  OR DISAPPROVED BY  THE SECURITIES AND
  EXCHANGE  COMMISSION  OR  ANY  STATE  SECURITIES  COMMISSION  NOR  HAS   THE
    SECURITIES   AND   EXCHANGE   COMMISSION   OR   ANY   STATE   SECURITIES
      COMMISSION  PASSED   UPON  THE   ACCURACY   OR  ADEQUACY   OF   THIS
       PROSPECTUS  SUPPLEMENT  OR  THE PROSPECTUS  TO  WHICH  IT RELATES.
           ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

                               ------------------

<TABLE>
<CAPTION>
                                                       INITIAL PUBLIC       UNDERWRITING        PROCEEDS TO
                                                     OFFERING PRICE (1)     DISCOUNT (2)       COMPANY (1)(3)
                                                     ------------------  ------------------  ------------------
<S>                                                  <C>                 <C>                 <C>
Per Note...........................................         100%               0.650%             99.350%
Total..............................................     $150,000,000          $975,000          $149,025,000
<FN>
- ---------
(1)  Plus accrued interest from May 15, 1995.
(2)  The Company  has  agreed  to indemnify  the  Underwriters  against  certain
     liabilities, including liabilities under the Securities Act of 1933.
(3)  Before deducting expenses payable by the Company estimated at $150,000.
</TABLE>

                               ------------------

    The  Notes  offered hereby  are offered  severally  by the  Underwriters, as
specified herein, subject to receipt and acceptance by them and subject to their
right to reject any order in whole or  in part. It is expected that delivery  of
the  Notes will be  made in book-entry  form only through  the facilities of The
Depository Trust Company on  or about May 17,  1995 against payment therefor  in
immediately available funds.

GOLDMAN, SACHS & CO.
                 LAZARD FRERES & CO.
                            LEHMAN BROTHERS
                                                            SALOMON BROTHERS INC
                                  ------------

            The date of this Prospectus Supplement is May 10, 1995.
<PAGE>
    IN  CONNECTION WITH THIS OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT
TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE  MARKET PRICE OF THE NOTES  OFFERED
HEREBY  AT LEVELS ABOVE THOSE WHICH MIGHT  OTHERWISE PREVAIL IN THE OPEN MARKET.
SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME.

                               ------------------

                                USE OF PROCEEDS

    The Company will utilize  the net proceeds from  the Notes to repay  certain
indebtedness  incurred  for working  capital purposes.  Such indebtedness  is of
varying maturities of less than nine  months and bears interest at rates  within
the range of 5.9% to 6.1% per annum.

                              DESCRIPTION OF NOTES

    THE  FOLLOWING  DESCRIPTION OF  THE PARTICULAR  TERMS  OF THE  NOTES OFFERED
HEREBY SUPPLEMENTS,  AND  TO THE  EXTENT  INCONSISTENT THEREWITH  REPLACES,  THE
DESCRIPTION  OF THE GENERAL TERMS AND PROVISIONS  OF THE SECURITIES SET FORTH IN
THE ACCOMPANYING PROSPECTUS, TO WHICH DESCRIPTION REFERENCE IS HEREBY MADE.  THE
STATEMENTS  HEREIN CONCERNING THE NOTES  AND THE INDENTURE DO  NOT PURPORT TO BE
COMPLETE. ALL SUCH STATEMENTS  ARE QUALIFIED IN THEIR  ENTIRETY BY REFERENCE  TO
THE  ACCOMPANYING PROSPECTUS  AND THE PROVISIONS  OF THE INDENTURE,  THE FORM OF
WHICH HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

    The Company's 6.80%  Notes due  May 15,  2005 (the  "Notes") offered  hereby
constitute  a single series of Securities to be issued under an Indenture, dated
as of October 1, 1993, between the Company and Harris Trust and Savings Bank, as
Trustee (the "Trustee"), and will be limited to $150,000,000 aggregate principal
amount. As  of  March  31,  1995, $200,000,000  aggregate  principal  amount  of
Securities  was outstanding under  the Indenture. The  Trustee will initially be
the Securities Registrar and Paying Agent  (the "Paying Agent"). The Notes  will
be issued only in registered form without coupons in denominations of $1,000 and
integral multiples thereof.

    The Notes will be represented by one or more Global Securities registered in
the  name of a nominee of  DTC. The ownership interests ("Book-Entry Interests")
in such  Global Securities  will be  shown  on, and  transfers thereof  will  be
effected  only through, records maintained by DTC or its nominee for such Global
Securities and on the records of DTC participants. Except as described below and
in the  accompanying Prospectus,  owners  of Book-Entry  Interests will  not  be
considered  the Holders  thereof and  will not  be entitled  to receive physical
delivery of Notes in definitive form. In the event that the book-entry system is
discontinued, including in the event DTC is  at any time unwilling or unable  to
continue  as Depository,  the Company will  issue individual Notes  to owners of
Book-Entry Interests in exchange for the Global Securities. See "Description  of
Securities -- Book-Entry Securities" in the accompanying Prospectus.

    Settlement  for the  Notes will be  made by the  Underwriters in immediately
available funds, and all payments of principal and interest on the Notes will be
made by  the  Company  in  immediately available  funds.  Secondary  trading  in
long-term  notes and  debentures of  corporate issuers  is generally  settled in
clearinghouse or  next-day funds.  In  contrast, the  Notes  will trade  in  the
Depository's  Same-Day  Funds Settlement  System  until maturity,  and secondary
market trading  activity  in  the  Notes  will  therefore  be  required  by  the
Depository  to settle in immediately available  funds. No assurance can be given
as to  the effect,  if any,  of  settlement in  immediately available  funds  on
trading activity in the Notes.

    The Notes will mature on May 15, 2005. Interest on the Notes will be payable
semi-annually  on each May 15 and November 15 (each an "Interest Payment Date"),
commencing November 15,  1995. Interest  payable on each  Interest Payment  Date
will include interest accrued from May 15, 1995 or from the most recent Interest
Payment  Date to  which interest  has been paid  or duly  provided for. Interest
payable on any Interest Payment Date will be payable to the person in whose name
a Note (or any predecessor Note) is  registered at the close of business on  the
May  1 or November 1,  as the case may be,  next preceding such Interest Payment
Date. Payments of principal and interest  to owners of Book-Entry Interests  are
expected  to be made  in accordance with the  Depository's and its participants'
procedures in effect from time to time. Principal of, and interest on, Notes  in
definitive form will be payable at the

                                      S-2
<PAGE>
office  or  agency  of  the  Company maintained  for  such  purpose  in Chicago,
Illinois, which  initially will  be the  office of  an affiliate  of the  Paying
Agent,  provided that  payment of  interest may  be made,  at the  option of the
Company, by check mailed to the person entitled thereto.

    The Notes  are not  redeemable or  repayable prior  to maturity  and do  not
provide for any sinking fund.

    The  Indenture does  not contain covenants  or other  provisions designed to
afford holders  of the  Notes protection  in  the event  of a  highly  leveraged
transaction, change in credit rating or other similar occurrence.

                                  UNDERWRITING

    Subject to the terms and conditions set forth in the Underwriting Agreement,
the Company has agreed to sell to each of the Underwriters named below, and each
of  the Underwriters has  severally agreed to purchase,  the principal amount of
the Notes set forth opposite its name below:

<TABLE>
<CAPTION>
                                                                                        PRINCIPAL AMOUNT
UNDERWRITER                                                                                 OF NOTES
- --------------------------------------------------------------------------------------  ----------------
<S>                                                                                     <C>
Goldman, Sachs & Co...................................................................  $     37,500,000
Lazard Freres & Co....................................................................        37,500,000
Lehman Brothers Inc...................................................................        37,500,000
Salomon Brothers Inc..................................................................        37,500,000
                                                                                        ----------------
  Total...............................................................................  $    150,000,000
                                                                                        ----------------
                                                                                        ----------------
</TABLE>

    Under  the  terms  and  conditions   of  the  Underwriting  Agreement,   the
Underwriters  are committed  to take and  pay for all  of the Notes,  if any are
taken.

    The Underwriters  propose to  offer the  Notes in  part directly  to  retail
purchasers  at the initial public offering price  set forth on the cover page of
this Prospectus Supplement, and  in part to certain  securities dealers at  such
price  less a concession not in excess of  0.40% of the principal amount of such
Notes. The Underwriters may  allow, and such dealers  may reallow, a  concession
not  to  exceed 0.25%  of the  principal amount  of the  Notes to  certain other
brokers and dealers. After the  Notes are released for  sale to the public,  the
offering  price and other selling  terms may from time to  time be varied by the
Underwriters.

    The Notes are a new issue  of securities with no established trading  market
and will not be listed on any national securities exchange. The Company has been
advised  by the Underwriters that they intend to make a market in the Notes, but
are not obligated to  do so and  may discontinue any  market-making at any  time
without  notice. No assurance  can be given  as to the  liquidity of the trading
market, if any, for the Notes.

    From time to  time the  Underwriters and  certain of  their affiliates  have
engaged,  and  may  in the  future  engage,  in transactions  with,  and perform
services for, the Company in the ordinary course of business.

    The Company has agreed to indemnify the several Underwriters against certain
liabilities, including liabilities under the Securities Act of 1933.

                                 LEGAL OPINIONS

    Certain legal matters in connection with  the offering of the Notes will  be
passed  upon for the  Company by Jose  M. de Lasa,  Esq., Senior Vice President,
Secretary and  General Counsel  of the  Company  and by  Mayer, Brown  &  Platt,
Chicago,  Illinois, and for the Underwriters  by Skadden, Arps, Slate, Meagher &
Flom, Chicago, Illinois. As  of April 30, 1995,  Mr. de Lasa beneficially  owned
20,000  shares of common stock of the Company and held options to acquire 80,002
shares of such common stock. Skadden, Arps,  Slate, Meagher & Flom from time  to
time represents the Company in connection with certain other matters.

                                      S-3
<PAGE>
P R O S P E C T U S

                                  $500,000,000

                              ABBOTT LABORATORIES

                                DEBT SECURITIES

                                  ------------

    Abbott  Laboratories (the "Company") intends from  time to time to issue its
unsecured debt securities (the "Securities") from which the Company will receive
up to an  aggregate amount  of $500,000,000 in  proceeds (or  its equivalent  in
foreign  currencies or currency units). The  Securities will be offered for sale
in amounts, at prices and on terms to be determined when an agreement to sell is
made or at the time of sale, as the case may be. The Securities may be sold  for
U.S.  dollars, foreign denominated currency or European Currency Units ("ECUs"),
and principal of and any interest on  the Securities may likewise be payable  in
U.S. dollars, foreign denominated currency or ECUs. For each issue of Securities
in   respect  of  which  this  Prospectus   is  being  delivered  (the  "Offered
Securities"), there is  an accompanying Prospectus  Supplement (the  "Prospectus
Supplement") that sets forth the title, designation, aggregate principal amount,
designated  currency or currency units, rate (which may be fixed or variable) or
method of  calculation of  interest  and dates  for payment  thereof,  maturity,
priority,   premium,  if  any,  authorized  denominations,  initial  price,  any
redemption or prepayment rights at the option of the Company or the holder,  any
terms  for sinking fund payments,  any listing on a  securities exchange and the
initial public  offering price,  the form  of the  Securities (which  may be  in
registered  or permanent  global form)  and other  special terms  of the Offered
Securities, together with the  terms of the offering  of the Offered  Securities
and the net proceeds to the Company from the sale thereof.

    The  Securities  may be  offered  directly to  purchasers  or to  or through
agents, underwriters  or dealers  designated from  time to  time, or  through  a
combination of those methods of sale. If any underwriters or agents are involved
in the offering of the Offered Securities in respect of which this Prospectus is
being  delivered, the  names of such  agents or underwriters  and any applicable
fee, commission and  discount arrangements with  them will be  set forth in  the
Prospectus  Supplement.  See "Plan  of Distribution."  The  net proceeds  to the
Company from such offering will also be set forth in the Prospectus Supplement.

                              -------------------

THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
    EXCHANGE COMMISSION OR  ANY STATE SECURITIES  COMMISSION NOR HAS  THE
       SECURITIES  AND EXCHANGE  COMMISSION OR  ANY STATE SECURITIES
            COMMISSION PASSED UPON THE  ACCURACY OR ADEQUACY  OF
                THIS  PROSPECTUS. ANY REPRESENTATION TO THE
                          CONTRARY IS A CRIMINAL OFFENSE.

                              -------------------

                The date of this Prospectus is October 1, 1993.
<PAGE>
    NO   PERSON  IS  AUTHORIZED   TO  GIVE  ANY  INFORMATION   OR  TO  MAKE  ANY
REPRESENTATIONS OTHER THAN THOSE  CONTAINED IN OR  INCORPORATED BY REFERENCE  IN
THIS  PROSPECTUS  OR  ANY PROSPECTUS  SUPPLEMENT  AND,  IF GIVEN  OR  MADE, SUCH
INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED
BY THE COMPANY OR  ANY UNDERWRITER. NEITHER THIS  PROSPECTUS NOR ANY  PROSPECTUS
SUPPLEMENT CONSTITUTES AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY
SECURITIES  OTHER THAN THE REGISTERED SECURITIES TO WHICH IT RELATES OR AN OFFER
TO SELL OR A SOLICITATION  OF AN OFFER TO BUY  SUCH SECURITIES TO ANY PERSON  IN
ANY  JURISDICTION TO WHOM IT  IS UNLAWFUL TO MAKE  SUCH OFFER OR SOLICITATION IN
SUCH JURISDICTION. NEITHER  THE DELIVERY OF  THIS PROSPECTUS NOR  ANY SALE  MADE
HEREUNDER  SHALL UNDER ANY  CIRCUMSTANCES CREATE ANY  IMPLICATION THAT THERE HAS
BEEN NO CHANGE IN THE AFFAIRS OF THE  COMPANY SINCE THE DATE HEREOF OR THAT  THE
INFORMATION  CONTAINED OR INCORPORATED BY REFERENCE  HEREIN IS CORRECT AS OF ANY
TIME SUBSEQUENT TO ITS DATE.

                             AVAILABLE INFORMATION

    The Company is subject to  the informational requirements of the  Securities
Exchange  Act  of  1934, as  amended  (the  "Exchange Act"),  and  in accordance
therewith files  reports,  proxy  statements  and  other  information  with  the
Securities  and  Exchange  Commission (the  "Commission").  Such  reports, proxy
statements and  other information  filed by  the Company  can be  inspected  and
copied  at the office of the Commission at Room 1024, Judiciary Plaza, 450 Fifth
Street, N.W., Washington, D.C. 20549, as well as at the Regional Offices of  the
Commission  at Citicorp  Center, 500 West  Madison Street,  Suite 1400, Chicago,
Illinois 60661-2511, and  Seven World Trade  Center, Suite 1300,  New York,  New
York  10048. Copies of such information can  be obtained by mail from the Public
Reference Section of  the Commission at  Room 1024, Judiciary  Plaza, 450  Fifth
Street,  N.W.,  Washington,  D.C.  20549, at  prescribed  rates.  Reports, proxy
statements and other information concerning the Company can also be inspected at
the office of the New York Stock  Exchange, 20 Broad Street, New York, New  York
10005,  at the office of  the Chicago Stock Exchange,  440 South LaSalle Street,
Chicago, Illinois 60605, and  at the office of  the Pacific Stock Exchange,  301
Pine  Street, San Francisco, California 94104. The Company has securities listed
on each of the aforementioned exchanges.

    This  Prospectus  constitutes  a  part  of  a  registration  statement  (the
"Registration  Statement") filed  by the Company  with the  Commission under the
Securities Act of 1933, as amended (the "Securities Act"). This Prospectus omits
certain  of  the  information  contained  in  the  Registration  Statement,  and
reference  is  hereby made  to the  Registration Statement  and to  the exhibits
thereto for further information with respect to the Company and the Securities.

    The Company is not required, nor does it intend, to provide annual or  other
reports to holders of the Securities. However, such reports will be available to
such holders upon request. See "Documents Incorporated by Reference."

                      DOCUMENTS INCORPORATED BY REFERENCE

    The following documents filed by the Company under the Exchange Act with the
Commission are incorporated herein by reference:

    (1) The Company's Annual Report on Form 10-K for the year ended December 31,
       1992.

    (2) The Company's Quarterly Reports on Form 10-Q for the quarter ended March
       31, 1993 and the quarter ended June 30, 1993.

    All  documents filed by the Company pursuant to Sections 13(a), 13(c), 14 or
15(d) of the Exchange  Act after the  date of this Prospectus  and prior to  the
termination  of the offering of the Securities offered hereby shall be deemed to
be incorporated in this Prospectus by reference and to be a part hereof from the
date of  filing  of  such  documents. Any  statement  contained  in  a  document
incorporated or deemed to be incorporated by reference herein shall be deemed to
be  modified or superseded for purposes of  this Prospectus to the extent that a
statement contained herein  or in  any other subsequently  filed document  which
also  is  or  is deemed  to  be  incorporated by  reference  herein  modifies or
supersedes such statement. Any  such statement so  modified or superseded  shall
not be deemed, except as so modified or superseded, to constitute a part of this
Prospectus.

    The Company will provide without charge, upon the written or oral request by
any  person to whom  this Prospectus is delivered,  a copy of any  or all of the
documents incorporated by reference in  this Prospectus, other than exhibits  to
such  documents (unless such exhibits are specifically incorporated by reference
into such documents).  Such requests  should be  directed to:  Lael F.  Johnson,
Senior  Vice President, Secretary and  General Counsel, Abbott Laboratories, One
Abbott Park Road, Abbott Park, Illinois 60064-3500 (telephone (708) 937-6100).

                                       2
<PAGE>
                                  THE COMPANY

    The Company  is  an Illinois  corporation,  incorporated in  1900.  As  used
throughout  the text of  this document, references to  the "Company" include the
Company and its consolidated subsidiaries, unless otherwise indicated or  unless
the  context otherwise requires. The Company's  corporate offices are located at
One Abbott Park Road, Abbott Park, Illinois 60064-3500. Its telephone number  is
(708) 937-6100.

    The Company's principal business is the discovery, development, manufacture,
and  sale of  a broad  and diversified  line of  human health  care products and
services. Among  the  Company's  products  is a  line  of  adult  and  pediatric
pharmaceuticals  and  nutritionals. These  products  are sold  primarily  on the
prescription or recommendation of physicians or other health care professionals.
This   line   also   includes   agricultural   and   chemical   products,   bulk
pharmaceuticals, and consumer products. In addition, the Company produces a line
of  hospital and laboratory products which includes diagnostic systems for blood
banks, hospitals,  commercial laboratories,  and alternate-care  testing  sites;
intravenous   and  irrigation  fluids   and  related  administration  equipment,
including electronic drug  delivery systems;  drugs and  drug delivery  systems;
anesthetics;  critical care products;  and other medical  specialty products for
hospitals and alternate-care sites.

    The Company purchases,  in the  ordinary course of  business, necessary  raw
materials  and  supplies essential  to  the Company's  operations  from numerous
suppliers in the  United States and  overseas. The Company  markets products  in
approximately  130 countries  through affiliates  and distributors.  Most of the
Company's products are sold both in  and outside the United States. The  Company
employs  approximately  49,500  persons  in  its  various  offices,  plants  and
facilities located throughout  North America,  South America,  Europe, Asia  and
Australia.

                       RATIO OF EARNINGS TO FIXED CHARGES

    The following table sets forth the ratio of earnings to fixed charges of the
Company (including its majority-owned subsidiaries, whether or not consolidated,
its  proportionate  share of  any  fifty-percent-owned persons,  and  any income
received (but  not  undistributed  amounts)  from  less-than-fifty-percent-owned
persons) for the periods indicated:

<TABLE>
<CAPTION>
                                                              YEAR ENDED DECEMBER 31,
              SIX MONTHS ENDED                 -----------------------------------------------------
                JUNE 30, 1993                    1992       1991       1990       1989       1988
- ---------------------------------------------  ---------  ---------  ---------  ---------  ---------

<S>                                            <C>        <C>        <C>        <C>        <C>
                    21.1                            18.0       16.0       12.1       13.4       11.0
</TABLE>

    For the purpose of calculating this ratio, (i) earnings have been calculated
by  adjusting net earnings for taxes  on earnings; interest expense; capitalized
interest  cost,  net  of   amortization;  equity  in   earnings  of  less   than
fifty-percent-owned persons, less dividends received; minority interest; and the
portion  of  rentals representative  of the  interest  factor, (ii)  the Company
considers one-third of rental  expense to be the  amount representing return  on
capital,  and  (iii) fixed  charges comprise  total interest  expense, including
capitalized interest and such portion of rentals. A statement setting forth  the
computation of the ratios of earnings to fixed charges is filed as an exhibit to
the Registration Statement of which this Prospectus is a part.

                                USE OF PROCEEDS

    Except  as otherwise set forth in  the Prospectus Supplement relating to the
Offered Securities, the net proceeds to be received by the Company from the sale
of the Securities will be added to the general funds of the Company and will  be
used  for  general  corporate  purposes,  including  repayment  of indebtedness,
retirement of long-term and  short-term debt and the  purchase of shares of  the
Company's  common stock. Pending such use,  the net proceeds will be temporarily
invested in short-term instruments.

                                       3
<PAGE>
                           DESCRIPTION OF SECURITIES

    The Securities  are  to be  issued  under an  Indenture  (the  "Indenture"),
between  the  Company  and  Harris  Trust  and  Savings  Bank,  as  Trustee (the
"Trustee"), a  copy  of  which  is  filed as  an  exhibit  to  the  Registration
Statement. The following summaries of certain provisions of the Indenture do not
purport  to be complete and are subject  to, and are qualified in their entirety
by reference to, all the provisions of the Indenture, including the  definitions
therein  of certain terms. Wherever particular  Sections or defined terms of the
Indenture are  referred to,  such  Sections or  defined terms  are  incorporated
herein by reference.

    The  following  sets  forth  certain general  terms  and  provisions  of the
Securities offered hereby. The particular terms of the Securities offered by any
Prospectus Supplement  (the  "Offered  Securities") will  be  described  in  the
Prospectus  Supplement  relating  to such  Offered  Securities  (the "Applicable
Prospectus Supplement").

GENERAL

    The Indenture does  not limit the  amount of Securities  that may be  issued
thereunder  and Securities may be issued thereunder  from time to time in one or
more series. The Securities will be unsecured and unsubordinated obligations  of
the  Company  and  will  rank  equally  and  ratably  with  other  unsecured and
unsubordinated obligations of the Company.

    Unless  otherwise  indicated  in   the  Applicable  Prospectus   Supplement,
principal  of, premium, if any, and interest  on the Securities will be payable,
and the transfer of Securities will be  registrable, at the office or agency  to
be  maintained  by the  Company in  Chicago and  at any  other office  or agency
maintained by the Company for such  purpose. The Securities will be issued  only
in  fully registered form without coupons and, unless otherwise indicated in the
Applicable  Prospectus  Supplement,  in  denominations  of  $1,000  or  integral
multiples  thereof.  No service  charge  will be  made  for any  registration of
transfer or exchange of the Securities, but the Company may require payment of a
sum sufficient  to  cover  any  tax or  other  governmental  charge  imposed  in
connection therewith.

    The  Applicable Prospectus Supplement  will describe the  following terms of
the Offered Securities: (1) the title  of the Offered Securities; (2) any  limit
on  the aggregate principal amount of the  Offered Securities; (3) the Person to
whom any interest on the Offered Securities shall be payable, if other than  the
person  in whose name that  Security (or one or  more Predecessor Securities) is
registered at  the  close  of business  on  the  Regular Record  Date  for  such
interest; (4) the date or dates on which the principal of the Offered Securities
is  payable; (5) the  percentage of the  principal amount for  which the Offered
Securities will  be  issued; (6)  the  rate or  rates  (which may  be  fixed  or
variable)  at which the Offered Securities shall  bear interest or the method by
which such rate or  rates shall be  determined, if any, the  date or dates  from
which  any such interest shall  accrue, the Interest Payment  Dates on which any
such interest shall  be payable  and the Regular  Record Date  for the  interest
payable  on  any  Interest Payment  Date;  (7)  the place  or  places  where the
principal of and  any premium and  interest on the  Offered Securities shall  be
payable;  (8) the period or  periods within which, the  price or prices at which
and the terms and conditions upon which the Offered Securities may be  redeemed,
in  whole or in part, at the option  of the Company; (9) the obligation, if any,
of the Company  to redeem  or purchase the  Offered Securities  pursuant to  any
sinking  fund or analogous provisions  or at the option  of a Holder thereof and
the period or periods within which, the  price or prices at which and the  terms
and conditions upon which the Offered Securities shall be redeemed or purchased,
in  whole  or  in  part,  pursuant  to  such  obligation;  (10)  if  other  than
denominations of $1,000 and any integral multiple thereof, the denominations  in
which the Offered Securities shall be issuable; (11) the currency, currencies or
currency units in which payment of the principal of and any premium and interest
on  any Offered Securities  shall be payable  if other than  the currency of the
United States of America; (12) if the amount of payments of principal of or  any
premium  or interest on any Offered  Securities may be determined with reference
to an index or formula,  the manner in which  such amounts shall be  determined;
(13) if the principal of or any premium or interest on any Offered Securities is
to  be payable, at  the election of the  Company or a Holder  thereof, in one or
more currencies or currency units other than that or those in which the  Offered
Securities  are stated to be payable, the currency, currencies or currency units
in which payment of the principal of and any

                                       4
<PAGE>
premium and interest on the Offered Securities as to which such election is made
shall be payable, and the periods within which and the terms and conditions upon
which such election  is to  be made;  (14) if  other than  the principal  amount
thereof,  the portion  of the principal  amount of the  Offered Securities which
shall be payable upon declaration of acceleration of the Maturity thereof;  (15)
the  applicability of  the provisions  described under  "Defeasance and Covenant
Defeasance"; (16) if the Offered Securities will be issuable only in the form of
a Book-Entry Security as described under "Book-Entry Securities," the depository
appointed by the Company (the "Depository")  or its nominee with respect to  the
Offered Securities and the circumstances under which the Book-Entry Security may
be  registered for  transfer or exchange  or authenticated and  delivered in the
name of a Person other  than the Depository or its  nominee; and (17) any  other
terms of the Offered Securities.

    The  Securities may  be issued as  Original Issue Discount  Securities to be
offered and sold at a substantial discount below their stated principal  amount.
Federal  income tax consequences and  other special considerations applicable to
Original Issue Discount  Securities and  any Securities treated  as having  been
issued  with original  issue discount  for Federal  income tax  purposes will be
described in  the Applicable  Prospectus  Supplement. "Original  Issue  Discount
Securities"  means  any Security  which  provides for  an  amount less  than the
principal amount  thereof  to  be  due  and  payable  upon  the  declaration  of
acceleration  of the Maturity thereof upon the occurrence of an Event of Default
and the continuation thereof.

    The Indenture does  not contain  covenants or other  provisions designed  to
afford  holders of the Securities protection in  the event of a highly leveraged
transaction, change in credit rating or other similar occurrence.

BOOK-ENTRY SECURITIES

    Unless otherwise provided in the Prospectus Supplement, the Securities  will
be represented by one or more certificates (the "Global Securities"). The Global
Security  representing Securities will  be deposited with, or  on behalf of, The
Depository Trust Company ("DTC"), or other successor depository appointed by the
Company (DTC or such other depository is herein referred to as the "Depository")
and registered in the  name of the Depository  or its nominee. Unless  otherwise
provided  in  the  Prospectus  Supplement,  Securities  will  not  be  issued in
definitive form. DTC  currently limits  the maximum denomination  of any  single
Global Security to $150,000,000.

    DTC is a limited-purpose trust company organized under the laws of the State
of  New York, a member  of the Federal Reserve  System, a "clearing corporation"
within the  meaning of  the New  York Uniform  Commercial Code  and a  "clearing
agency"  registered pursuant to the provisions  of Section 17A of the Securities
Exchange Act of 1934. DTC was created to hold securities of its participants and
to facilitate the clearance and settlement of securities transactions among  its
participants  in  such  securities  through  electronic  book-entry  changes  in
accounts of the participants, thereby eliminating the need for physical movement
of securities certificates.  DTC's participants include  securities brokers  and
dealers,  banks,  trust  companies,  clearing  corporations  and  certain  other
organizations, some  of which  (and/or their  representatives) own  DTC. DTC  is
owned  by a number of its participants and by the New York Stock Exchange, Inc.,
the American Stock Exchange,  Inc., and the  National Association of  Securities
Dealers,  Inc. Access  to DTC's book-entry  system is also  available to others,
such as  banks, brokers,  dealers and  trust companies,  that clear  through  or
maintain  a  custodial  relationship  with  a  participant,  either  directly or
indirectly. The rules applicable  to DTC and its  participants are on file  with
the Commission.

    Upon  the  issuance by  the Company  of Securities  represented by  a Global
Security, DTC will credit, on  its book-entry registration and transfer  system,
the  respective principal amounts  of the Securities  represented by such Global
Security to the accounts of participants.  The accounts to be credited shall  be
designated  by  the underwriters,  dealers  or agents.  Ownership  of beneficial
interests in the Global Security will be limited to participants or persons that
hold interests  through  participants.  Ownership  of  beneficial  interests  in
Securities represented by the Global Security will be shown on, and the transfer
of that ownership will be effected only through, records maintained by DTC (with
respect to interests of

                                       5
<PAGE>
participants  in  DTC), or  by  participants in  DTC  or persons  that  may hold
interests  through  such  participants  (with  respect  to  persons  other  than
participants in DTC). The laws of some states require that certain purchasers of
securities  take physical delivery  of such securities  in definitive form. Such
limits and such laws may impair the ability to transfer beneficial interests  in
the Global Security.

    So  long as the Depository  for the Global Security,  or its nominee, is the
registered owner of the  Global Security, the Depositor  or its nominee, as  the
case  may be,  will be  considered the  sole owner  or holder  of the Securities
represented by  such  Global Security  for  all purposes  under  the  applicable
Indenture.   Except  as  provided  below,  owners  of  beneficial  interests  in
Securities represented  by the  Global Security  will not  be entitled  to  have
Securities  represented by such Global Security  registered in their names, will
not receive  or  be entitled  to  receive  physical delivery  of  Securities  in
definitive  form and will not be considered  the owners or holders thereof under
the applicable Indenture.

    Payments of principal of and interest, if any, on the Securities represented
by the Global Security registered in the name of DTC or its nominee will be made
by the Company through  the Trustee under the  applicable Indenture or a  paying
agent  (the "Paying Agent"), which may also  be the Trustee under the applicable
Indenture to DTC or its nominee, as the case may be, as the registered owner  of
the Global Security. Neither the Company, the Trustee, nor the Paying Agent will
have  any responsibility or liability for any  aspect of the records relating to
or payments made  on account  of beneficial  ownership interests  of the  Global
Security  or for maintaining,  supervising or reviewing  any records relating to
such beneficial ownership interests.

    The Company  has been  advised that  DTC,  upon receipt  of any  payment  of
principal  or interest in respect of  a Global Security, will credit immediately
the accounts of the related  participants with payment in amounts  proportionate
to their respective holdings in principal amount of beneficial interests in such
Global  Security  as shown  on  the records  of  DTC. The  Company  expects that
payments by participants to owners of beneficial interests in a Global  Security
will  be governed by standing customer  instructions and customary practices, as
is now the case  with securities held  for the accounts  of customers in  bearer
form  or registered  in "street  name" and  will be  the responsibility  of such
participants.

    If the Depository with respect to a Global Security is at any time unwilling
or unable to continue as Depository and a successor Depository is not  appointed
by  the Company  within 90  days, the Company  will issue  certificated notes in
exchange for the Securities represented by such Global Security.

    The  information  in  this  section   concerning  the  Depository  and   the
Depository's  book-entry system has been obtained  from sources that the Company
believes to  be  reliable, but  the  Company  takes no  responsibility  for  the
accuracy thereof.

CERTAIN COVENANTS OF THE COMPANY

    RESTRICTIONS  ON SECURED DEBT.  Unless  otherwise provided in the Prospectus
Supplement with respect to any series of  the Securities, if the Company or  any
Domestic  Subsidiary (as  defined below)  shall incur,  assume or  guarantee any
indebtedness for borrowed money secured by  a mortgage, pledge or other lien  on
any  Principal Domestic Property (as defined below) or on any shares of stock or
debt of  any  Domestic Subsidiary,  the  Company  shall secure,  or  cause  such
Domestic  Subsidiary to  secure, the  Securities equally  and ratably,  with (or
prior to) such indebtedness,  unless after giving  effect thereto the  aggregate
amount  of all such indebtedness so secured, together with all Attributable Debt
(as defined  below) in  respect  of sale  and leaseback  transactions  involving
Principal  Domestic Properties,  would not  exceed 15%  of the  Consolidated Net
Assets (as defined below)  of the Company. This  restriction will not apply  to,
and there shall be excluded in computing secured indebtedness for the purpose of
such  restriction, indebtedness secured  by (a) mortgages on  property of, or on
any shares  of stock  or debt  of, any  corporation existing  at the  time  such
corporation  becomes a Domestic Subsidiary, or arising thereafter otherwise than
in connection with borrowing money and pursuant to contracts entered into  prior
to  such  corporation becoming  a  Domestic Subsidiary,  (b)  mortgages securing
indebtedness of a  Domestic Subsidiary  to the  Company or  to another  Domestic
Subsidiary,  (c) mortgages  in favor of  U.S. or foreign  governmental bodies to
secure partial, progress, advance or other payments, (d) mortgages on  property,
shares  of  stock  or  debt,  purchase  money  mortgages  and  construction cost
mortgages

                                       6
<PAGE>
existing at  or incurred  within 120  days of  the time  of acquisition  thereof
(including  acquisition through merger or consolidation), (e) mortgages existing
on the first  date on  which a  Security is  authenticated by  the Trustee,  (f)
mortgages  incurred in connection with  pollution control, industrial revenue or
similar financings, and (g) any extension, renewal or refunding of any  mortgage
referred to in the foregoing clauses (a) through (f), inclusive.

    The  term "Subsidiary"  of the  Company means  any corporation  of which the
Company directly  or indirectly  owns  or controls  stock which  under  ordinary
circumstances (not dependent upon the happening of a contingency) has the voting
power  to  elect a  majority  of the  board  of directors  of  such corporation;
provided that the  term does not  include any  corporation that does  not own  a
Principal  Domestic  Property  and in  which  the Company's  investment,  in the
opinion of the Chief Executive Officer, President and Chief Financial Officer of
the Company, is not of material  importance to the total business conducted,  or
assets  owned, by the Company and its  Domestic Subsidiaries as an entirety. The
term "Domestic Subsidiary"  means a  Subsidiary of the  Company which  transacts
substantially  all of its business and  maintains substantially all of its fixed
assets within  the United  States (excluding  its territories,  possessions  and
Puerto  Rico), except a  Subsidiary which (a) is  engaged primarily in financing
operations outside  of the  United States  or in  leasing personal  property  or
financing  inventory,  receivables  or other  property  or  (b) does  not  own a
Principal Domestic Property.  The term "Principal  Domestic Property" means  any
facility  (together with the land on which it is erected and fixtures comprising
a  part  thereof)  used  primarily  for  manufacturing,  processing,   research,
warehousing  or  distribution,  located  in  the  United  States  (excluding its
territories, possessions and Puerto Rico), owned  or leased by the Company or  a
Subsidiary  of  the Company  and having  a net  book  value in  excess of  2% of
Consolidated Net Assets, other than any  such facility or portion thereof  which
is  a  pollution  control  facility  financed  by  state  or  local governmental
obligations or is not of material importance to the total business conducted  or
assets  owned  by the  Company and  its  Subsidiaries as  an entirety.  The term
"Consolidated Net Assets" means  the aggregate amount  of assets (less  reserves
and other deductible items) after deducting current liabilities, as shown on the
consolidated  balance sheet of the Company and its Subsidiaries contained in the
latest annual report to the stockholders  of the Company prepared in  accordance
with  generally  accepted accounting  principles.  The term  "Attributable Debt"
means the  present value  (discounted at  the rate  of 8%  per annum  compounded
monthly)  of the obligations for rental payments  required to be paid during the
remaining term of any lease of more than 12 months.

    RESTRICTIONS ON  SALES AND  LEASEBACKS.   Unless otherwise  provided in  the
Prospectus  Supplement with respect to any series of the Securities, neither the
Company nor  any Domestic  Subsidiary  may enter  into  any sale  and  leaseback
transaction  involving  any  Principal  Domestic  Property,  the  completion  of
construction and commencement of full operation of which has occurred more  than
120 days prior thereto, unless (a) the Company or such Domestic Subsidiary could
incur  a mortgage on such property  under the restrictions described above under
"Restrictions on Secured Debt" in an amount equal to the Attributable Debt  with
respect  to  the  sale and  leaseback  transaction without  equally  and ratably
securing  the  Securities  or  (b)  the  Company  or  a  wholly-owned   Domestic
Subsidiary,  within  120 days,  applies  to the  retirement  of its  funded debt
(defined as indebtedness  for borrowed  money having a  maturity of,  or by  its
terms  extendible or renewable  for, a period  of more than  12 months after the
date of determination of the amount thereof) an amount not less than the greater
of (i) the net proceeds  of the sale of  the Principal Domestic Property  leased
pursuant  to such arrangement or  (ii) the fair value  of the Principal Domestic
Property so  leased (subject  to credits  for certain  voluntary retirements  of
funded  debt).  This  restriction  will  not apply  to  any  sale  and leaseback
transaction (a) between the  Company and a  wholly-owned Domestic Subsidiary  or
between wholly-owned Domestic Subsidiaries or (b) involving the taking back of a
lease for a period of less than three years.

EVENTS OF DEFAULT

    Any  one of the following  events will constitute an  Event of Default under
the Indenture with respect to Securities of  any series: (a) failure to pay  any
interest  on any Security  of that series  when due, continued  for 30 days; (b)
failure to pay principal of or any  premium on any Security of that series  when
due;  (c) failure to deposit  any sinking fund payment,  when due, in respect of
any Security of that  series; (d) failure  to perform, or  breach of, any  other
covenant or warranty of the Company in the Indenture

                                       7
<PAGE>
(other  than a covenant  included in the  Indenture solely for  the benefit of a
series of Securities thereunder  other than that series)  continued for 90  days
after  written  notice  as provided  in  the  Indenture; (e)  certain  events in
bankruptcy, insolvency or reorganization of the Company; or (f) any other  Event
of Default provided with respect to Securities of that series.

    If  any Event of Default with respect to the Securities of any series at the
time Outstanding occurs and is continuing, either the Trustee or the Holders  of
at  least 25 percent in aggregate principal amount of the Outstanding Securities
of that series may declare the principal  amount (or, if the Securities of  that
series  are Original  Issue Discount Securities,  such portion  of the principal
amount as may be specified in the  terms thereof) of all the Securities of  that
series  to be due  and payable immediately.  At any time  after a declaration of
acceleration with respect to Securities of any series has been made, but  before
a  judgment or decree based on acceleration  has been obtained, the Holders of a
majority in aggregate principal amount of Outstanding Securities of that  series
may, under certain circumstances, rescind and annul such acceleration.

    Reference  is made to  the Applicable Prospectus  Supplement relating to any
series of Offered Securities that are Original Issue Discount Securities for the
particular provisions  relating to  acceleration  of the  Stated Maturity  of  a
portion  of  the principal  amount  of such  series  of Original  Issue Discount
Securities upon  the occurrence  of an  Event of  Default and  the  continuation
thereof.

    The  Indenture  provides that,  subject to  the duty  of the  Trustee during
default to act with the required standard of care, the Trustee will be under  no
obligation  to exercise any of  its rights or powers  under the Indenture at the
request or  direction of  any of  the Holders,  unless such  Holders shall  have
offered  to the Trustee reasonable indemnity. Subject to such provisions for the
indemnification of the Trustee and to certain other conditions, the Holders of a
majority in  aggregate principal  amount of  the Outstanding  Securities of  any
series  will have the right  to direct the time,  method and place of conducting
any proceeding for any remedy available to the Trustee, or exercising any  trust
or  power  conferred on  the Trustee,  with  respect to  the Securities  of that
series.

    No Holder of any series of Securities  will have any right to institute  any
proceeding  with respect to  the Indenture or for  any remedy thereunder, unless
such Holder  shall have  previously given  to the  Trustee written  notice of  a
continuing  Event of Default  and unless the  Holders of at  least 25 percent in
principal amount of the  Outstanding Securities of that  series shall have  made
written  request, and offered reasonable indemnity,  to the Trustee to institute
such proceeding as  trustee, and the  Trustee shall not  have received from  the
Holders  of  a  majority  in  aggregate  principal  amount  of  the  Outstanding
Securities of that series a direction  inconsistent with such request and  shall
have  failed  to  institute  such  proceeding  within  60  days.  However,  such
limitations do not  apply to a  suit instituted by  a Holder of  a Security  for
enforcement  of payment of the principal of  and premium, if any, or interest on
such Security on or after the respective due dates expressed in such Security.

    The Company is required to furnish to the Trustee annually a statement as to
the performance by the Company of certain of its obligations under the Indenture
and as to any default in such performance.

MODIFICATION AND WAIVER

    Modifications and amendments of the Indenture may be made by the Company and
the Trustee with the  consent of the  Holders of not less  than the majority  in
aggregate  principal amount of the Outstanding  Securities of each series issued
under the Indenture  and affected  by the modification  or amendment;  provided,
however,  that no such modification or amendment may, without the consent of the
Holders of all Securities  affected thereby, (i) change  the Stated Maturity  of
the  principal  of, or  any  installment of  principal  of or  interest  on, any
Security; (ii)  reduce the  principal amount  of,  or the  premium, if  any,  or
(except  as otherwise provided in the Applicable Prospectus Supplement) interest
on, any Security (including in the  case of an Original Issue Discount  Security
the  amount payable upon acceleration of the maturity thereof); (iii) change the
place or currency of payment  of principal of, premium,  if any, or interest  on
any Security; (iv) impair the right to institute suit for the enforcement of any
payment  on any Security on or at the Stated Maturity thereof (or in the case of
redemption, on or after the Redemption

                                       8
<PAGE>
Date);  or  (v)  reduce  the  percentage  in  principal  amount  of  Outstanding
Securities  of  any  series,  the  consent  of  whose  Holders  is  required for
modification or amendment  of the  Indenture or  for waiver  of compliance  with
certain provisions of the Indenture or for waiver of certain defaults.

    The  Holders of  at least  a majority in  aggregate principal  amount of the
Outstanding Securities  of any  series may,  on behalf  of all  Holders of  that
series,  waive compliance by the Company  with certain restrictive provisions of
the Indenture. The Holders  of not less than  a majority in aggregate  principal
amount of the Outstanding Securities of any series may, on behalf of all Holders
of  that series, waive any past default under the Indenture, except a default in
the payment of principal, premium  or interest and in  respect of a covenant  or
provision  of  the Indenture  that  cannot be  modified  or amended  without the
consent of  the Holder  of each  Outstanding Security  of such  series  affected
thereby.

CONSOLIDATION, MERGER AND SALE OF ASSETS

    The  Company may  not consolidate  with or  merge into  any other  Person or
transfer or lease its assets substantially as an entirety to any Person and  may
not  permit any Person to merge into or consolidate with the Company or transfer
or lease its assets substantially as an entirety to the Company, unless (i)  any
successor  or purchaser is a corporation,  partnership, or trust organized under
the laws of the United States of America, any State or the District of Columbia,
and any such successor or purchaser expressly assumes the Company's  obligations
on  the Securities under a supplemental Indenture, (ii) immediately after giving
effect to the transaction no Event of Default, and no event which, after  notice
or  lapse of time or both, would become an Event of Default, shall have occurred
and be continuing, (iii) if properties  or assets of the Company become  subject
to  a mortgage  not permitted  by the Indenture,  the Company  or such successor
Person, as the case may be, takes  such steps as shall be necessary  effectively
to secure the Securities equally and ratably with (or prior to) all indebtedness
secured  thereby, and (iv) the Company has delivered to the Trustee an Officers'
Certificate and an Opinion of Counsel stating compliance with these provisions.

DEFEASANCE AND COVENANT DEFEASANCE

    The  Indenture  provides,  unless  otherwise  indicated  in  the  Applicable
Prospectus  Supplement with respect to the Offered Securities, that the Company,
at the Company's option, (a) will be discharged from any and all obligations  in
respect  of  the Securities  of any  series (except  for certain  obligations to
register the  transfer of  or exchange  of Securities  of such  series,  replace
stolen,  lost or mutilated  Securities of such  series, maintain paying agencies
and hold  moneys for  payment in  trust) or  (b) need  not comply  with  certain
restrictive covenants of the Indenture, including those described under "Certain
Covenants  of the Company," and  the occurrence of an  event described in clause
(d) under "Events of Default"  shall no longer be an  Event of Default, in  each
case,  if  the  Company deposits,  in  trust,  with the  Trustee  money  or U.S.
Government Obligations,  which  through  the payment  of  interest  thereon  and
principal  thereof  in accordance  with their  terms will  provide money,  in an
amount sufficient to pay all the principal of and interest on the Securities  of
such  series on the dates  such payments are due (which  may include one or more
redemption dates designated by the Company) in accordance with the terms of  the
Securities  of such series. Such a trust may be established only if, among other
things, (i) no  Event of Default  or event which  with the giving  of notice  or
lapse  of time, or  both, would become  an Event of  Default under the Indenture
shall have occurred and  be continuing on  the date of  such deposit, (ii)  such
deposit will not cause the Trustee to have any conflicting interest with respect
to other securities of the Company and (iii) the Company shall have delivered an
Opinion  of Counsel to  the effect that  the Holders will  not recognize income,
gain or loss  for Federal income  tax purposes as  a result of  such deposit  or
defeasance  and will be subject  to Federal income tax in  the same manner as if
such defeasance  had not  occurred, which  Opinion of  Counsel, in  the case  of
clause  (a) above,  must refer to  and be based  upon a published  ruling of the
Internal Revenue  Service, a  private  ruling of  the Internal  Revenue  Service
addressed to the Company, or otherwise a change in applicable Federal income tax
law occurring after the date of the Indenture. In the event the Company omits to
comply  with its remaining obligations under the Indenture after a defeasance of
the Indenture with respect  to the Securities of  any series as described  under
clause  (b) above and the Securities of such series are declared due and payable
because of the occurrence of any Event of Default, the amount of money and  U.S.
Government

                                       9
<PAGE>
Obligations  on deposit with the Trustee may  be insufficient to pay amounts due
on the Securities of such series at the time of the acceleration resulting  from
such  Event of Default.  However, the Company  will remain liable  in respect of
such payments.

CONCERNING THE TRUSTEE

    Harris Trust and Savings  Bank is Trustee under  the Indenture. The  Trustee
performs services for the Company in the ordinary course of business.

                              PLAN OF DISTRIBUTION

    The  Company may  sell the Securities  being offered  hereby through agents,
through underwriters and through  dealers, and Securities may  be sold to  other
purchasers  directly  or through  agents or  through a  combination of  any such
methods of sale.

    The distribution of the Securities may be effected from time to time in  one
or  more transactions at  a fixed price or  prices, which may  be changed, or at
market prices  prevailing  at  the time  of  sale,  at prices  related  to  such
prevailing market prices or at negotiated prices.

    Offers  to purchase Securities may be  solicited by agents designated by the
Company from  time  to  time. Any  such  agent,  who  may be  deemed  to  be  an
underwriter,  as that  term is  defined in the  Securities Act,  involved in the
offer or sale of the Securities in respect of which this Prospectus is delivered
will be named,  and any commissions  payable by  the Company to  such agent  set
forth,  in the  Applicable Prospectus Supplement.  Agents may  be entitled under
agreements that may be entered into  with the Company to indemnification by  the
Company  against certain liabilities, including liabilities under the Securities
Act, and such agents or their affiliates  may be customers of, extend credit  to
or  engage  in transactions  with or  perform  services for  the Company  in the
ordinary course  of  business.  Unless otherwise  indicated  in  the  Prospectus
Supplement,  any such agent will be acting on a reasonable efforts basis for the
period of its appointment.

    If any underwriters are utilized in the sale, the Company will enter into an
underwriting agreement with such  underwriters at the time  of sale to them  and
the names of the underwriters and the terms of the transaction will be set forth
in the Applicable Prospectus Supplement that will be used by the underwriters to
make  resales of the Securities in respect of which this Prospectus is delivered
to the public. The underwriters may be entitled under the relevant  underwriting
agreement  to  indemnification  by  the  Company  against  certain  liabilities,
including liabilities under the Securities  Act, and such underwriters or  their
affiliates  may be customers of, extend credit to or engage in transactions with
or perform services for the Company in the ordinary course of business.

    If dealers are utilized in  the sale of the  Securities in respect of  which
this  Prospectus is  delivered, the  Company will  sell such  Securities to such
dealers, as principal. The dealers may then resell such Securities to the public
at varying  prices to  be determined  by such  dealers at  the time  of  resale.
Dealers  may  be  entitled to  indemnification  by the  Company  against certain
liabilities, including liabilities under the Securities Act, and such dealers or
their affiliates may be customers of, extend credit to or engage in transactions
with or perform services for the Company in the ordinary course of business.

    The Securities are not proposed to  be listed on a securities exchange,  and
any  underwriters  or  dealers  will  not  be  obligated  to  make  a  market in
Securities. The Company cannot predict the activity or liquidity of any  trading
in the Securities.

                                 LEGAL OPINIONS

    Unless otherwise indicated in a supplement to this Prospectus, certain legal
matters in connection with the Securities offered hereby will be passed upon for
the Company by Lael F. Johnson, Esq., Senior Vice President, General Counsel and
Secretary of the Company and by Mayer, Brown & Platt, Chicago, Illinois, and for
the underwriters, dealers and agents, if any, by Skadden, Arps, Slate, Meagher &
Flom,  Chicago, Illinois. As of August  31, 1993, Mr. Johnson beneficially owned
122,645 shares  of common  stock of  the  Company and  held options  to  acquire
200,801 shares of such common stock. (These

                                       10
<PAGE>
amounts include 26,827 shares held by his spouse, of which Mr. Johnson disclaims
beneficial  ownership, and 20,679 shares held for  the benefit of Mr. Johnson in
the  Abbott  Laboratories  Stock  Retirement   Trust  pursuant  to  the   Abbott
Laboratories Stock Retirement Plan). The opinions of Mr. Johnson, Mayer, Brown &
Platt  and Skadden, Arps, Slate, Meagher & Flom may be conditioned upon, and may
be subject to certain assumptions regarding, future action required to be  taken
by  the Company and any underwriter(s), dealer(s) or agent(s) in connection with
the issuance  and sale  of  any particular  series  of Offered  Securities.  The
opinions  of Mr. Johnson, Mayer, Brown & Platt and Skadden, Arps, Slate, Meagher
& Flom with respect to  certain series of Offered  Securities may be subject  to
other  conditions  and assumptions,  as indicated  in the  Prospectus Supplement
describing such series. Skadden, Arps, Slate,  Meagher & Flom from time to  time
represents the Company in connection with certain other matters.

                                    EXPERTS

    The  consolidated financial statements and  schedules included in the Annual
Report on  Form 10-K  for the  year  ended December  31, 1992,  incorporated  by
reference in this Registration Statement, have been audited by Arthur Andersen &
Co.,  independent public accountants, as indicated in their reports with respect
thereto, and are included herein in reliance upon the authority of said firm  as
experts in giving said reports.

                                       11
<PAGE>
- ----------------------------------------------
- ----------------------------------------------
- ----------------------------------------------
- ----------------------------------------------

    NO  PERSON  HAS BEEN  AUTHORIZED  TO GIVE  ANY  INFORMATION OR  TO  MAKE ANY
REPRESENTATIONS OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS SUPPLEMENT OR  THE
PROSPECTUS  AND, IF GIVEN OR MADE,  SUCH INFORMATION OR REPRESENTATIONS MUST NOT
BE RELIED UPON  AS HAVING BEEN  AUTHORIZED. THIS PROSPECTUS  SUPPLEMENT AND  THE
PROSPECTUS DO NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO
BUY  ANY  SECURITIES  OTHER THAN  THE  SECURITIES DESCRIBED  IN  THIS PROSPECTUS
SUPPLEMENT OR AN OFFER TO BUY SUCH SECURITIES IN ANY CIRCUMSTANCES IN WHICH SUCH
OFFER OR  SOLICITATION IS  UNLAWFUL.  NEITHER THE  DELIVERY OF  THIS  PROSPECTUS
SUPPLEMENT  OR THE PROSPECTUS  NOR ANY SALE MADE  HEREUNDER OR THEREUNDER SHALL,
UNDER ANY CIRCUMSTANCES, CREATE ANY  IMPLICATION THAT THE INFORMATION  CONTAINED
HEREIN  OR THEREIN  IS CORRECT  AS OF ANY  TIME SUBSEQUENT  TO THE  DATE OF SUCH
INFORMATION.

                                ---------------

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                       PAGE
                                                     ---------
<S>                                                  <C>
                    PROSPECTUS SUPPLEMENT
Use of Proceeds....................................        S-2
Description of Notes...............................        S-2
Underwriting.......................................        S-3
Legal Opinions.....................................        S-3

                          PROSPECTUS
Available Information..............................          2
Documents Incorporated by Reference................          2
The Company........................................          3
Ratio of Earnings to Fixed Charges.................          3
Use of Proceeds....................................          3
Description of Securities..........................          4
Plan of Distribution...............................         10
Legal Opinions.....................................         10
Experts............................................         11
</TABLE>

                                  $150,000,000
                              ABBOTT LABORATORIES
                          6.80% NOTES DUE MAY 15, 2005

                                ---------------

                             PROSPECTUS SUPPLEMENT

                                 --------------

                              GOLDMAN, SACHS & CO.
                              LAZARD FRERES & CO.
                                LEHMAN BROTHERS

                              SALOMON BROTHERS INC

- -------------------------------
- -------------------------------
- -------------------------------
- -------------------------------


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission